• Radiation Therapy
    • Walter John Curran
    • Walter John Curran: Influence Statistics

      Walter John Curran

      Walter John Curran

      Show email address

      Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States of America | Department of Radiation Oncology, Winship Cancer ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Walter John Curran:Expert Impact

      Concepts for whichWalter John Curranhas direct influence:Radiation therapy,Brain metastases,Lung cancer,Cell lung,Radiation therapy oncology,Small cell,Stereotactic radiosurgery.

      Walter John Curran:KOL impact

      Concepts related to the work of other authors for whichfor which Walter John Curran has influence:Lung cancer,Brain metastases,Radiation therapy,Small cell,Stereotactic radiosurgery,Elderly patients,Glioblastoma multiforme.

      KOL Resume for Walter John Curran


      Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States of America


      Department of Radiation Oncology, Emory University Winship Cancer Institute, Atlanta, GA.

      Emory Univ. (United States)


      Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia; Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.

      Winship Cancer Institute of Emory University, Atlanta, GA;

      Emory University School of Medicine, Atlanta, GA


      Emory University, Atlanta, GA.

      NRG Oncology, and the Winship Cancer Institute, Atlanta, GA;


      Emory University, Winship Cancer Institute, Department of Radiation Oncology, Atlanta, Georgia, United States

      NRG Oncology/RTOG, and the Winship Cancer Institute, Atlanta, GA;

      Departments of1Radiation Oncology and.


      Department of Radiation Oncology, Rush University Medical Center, 500 South Paulina, 60612, Chicago, IL, USA

      Emory University, Atlanta, Georgia

      NRG Oncology/RTOG and Winship Cancer Institute, Atlanta, GA;


      Department of Radiation Oncology and Winship Cancer Institute.

      Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

      From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.).

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Walter John Curran is among the top experts in the world.
      Concept World rank
      purpose rpa classes #1
      psnr ncc #1
      hd cmd #1
      cycle gan #1
      rsr13 patients #1
      lmd death #1
      plane original images #1
      patients lrlgg #1
      273 increase #1
      registration accuracy terms #1
      previous partial #1
      magnitude hotspots #1
      grade higher esophagitis #1
      lvm segmentation ccta #1
      tracked frame #1
      patchbased random forest #1
      noncodeleted tumors #1
      lack gcc #1
      dose escalation rtog #1
      tirapazamine 159 #1
      patients 816 arm #1
      tumors total resection #1
      registration affine #1
      95 hypofractionated radiosurgery #1
      nmae noise #1
      localization attention #1
      mgd memory #1
      factlcs #1
      mlc25 treatment conformity #1
      preoperative neoadjuvant astro #1
      bortezomib hnc #1
      ncog studies #1
      srs surgery srs #1
      mi223 #1
      hfx patients #1
      predictive purpose #1
      sclc ctx #1
      u‐net‐gan #1
      embolization 18 patients #1
      late lung toxicity #1
      ajcc rtog #1
      5 extent #1
      survival data ncog #1
      msd hd #1
      prostate label mri #1
      pcv nonbudr patients #1
      iterative refinement model #1
      63 trt #1
      patients rtog studies #1
      cisplatinetoposide #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Walter John Curran

      KOL-Index: 28764

      BACKGROUND: We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung cancer.

      METHODS: In this open-label randomised, two-by-two factorial phase 3 study in 185 institutions in the USA and Canada, we enrolled patients (aged ≥ 18 years) with unresectable stage III non-small-cell lung cancer, a Zubrod ...

      Known for Conformal Radiotherapy | Patients Cetuximab | Cell Lung | Rtog 0617 | 3 Study
      KOL-Index: 17615

      BACKGROUND: Whole-breast irradiation after breast-conserving surgery for patients with early-stage breast cancer decreases ipsilateral breast-tumour recurrence (IBTR), yielding comparable results to mastectomy. It is unknown whether accelerated partial breast irradiation (APBI) to only the tumour-bearing quadrant, which shortens treatment duration, is equally effective. In our trial, we investigated whether APBI provides equivalent local tumour control after lumpectomy compared with ...

      Known for Breast Irradiation | Equivalence Trial | Patients Apbi | Accelerated Partial | Conserving Surgery
      KOL-Index: 16898

      PURPOSE: To identify in a multivariate analysis treatment-related factors predisposing patients (pts) with lung cancer to acute esophagitis, expressed as a severity grade or Esophagitis Index (EI).

      METHODS AND MATERIALS: Acute esophagitis is prospectively scored as an RTOG Grade in our institution during and after thoracic radiotherapy. Charts, toxicity forms and digitally reconstructed radiographs (DRRs) of all pts with lung cancer who received thoracic radiotherapy (RT) between 11/95 ...

      Known for Concurrent Chemotherapy | Lung Cancer | Multivariate Analysis | Severe Esophagitis | Irradiated Esophagus
      KOL-Index: 16840

      PURPOSE: Stereotactic radiosurgery (SRS) dose is limited by brain metastasis (BM) size. The study goal was to retrospectively determine whether there is a benefit for intracranial outcomes and overall survival (OS) for gross total resection with single-fraction SRS versus SRS alone for patients with large BMs.

      METHODS AND MATERIALS: A large BM was defined as ≥4 cm3 (2 cm in diameter) prior to the study. We reviewed the records of consecutive patients treated with single-fraction SRS ...

      Known for Stereotactic Radiosurgery | Large Brain | Srs Patients | Lung Neoplasms | Radiation Therapy
      KOL-Index: 15790

      BACKGROUND: Efforts to improve local control and survival by increasing the dose of once-daily radiation therapy beyond 70 Gray (Gy) for patients with malignant gliomas has yet been unsuccessful. Hyperfractionated radiation therapy (HF) should allow for delivery of a higher total dose without increasing normal tissue late effects, whereas accelerated hyperfractionated radiation therapy (AHF) may minimize tumor repopulation by shortening overall treatment time. The Radiation Therapy ...

      Known for Radiation Therapy | Malignant Gliomas | Patients Aa | Survival Dose | 5 Years
      KOL-Index: 15602

      PURPOSE: The recursive partitioning analysis (RPA) classes for malignant glioma patients were previously established using data on over 1500 patients entered on Radiation Therapy Oncology Group (RTOG) clinical trials. The purpose of the current analysis was to validate the RPA classes with a new dataset (RTOG 90-06), determine the predictive power of the RPA classes, and establish the usefulness of the database norms for the RPA classes.

      PATIENTS AND METHODS: There are six RPA classes ...

      Known for Rpa Classes | Malignant Glioma Patients | Radiation Therapy Oncology | Rtog 90 | Recursive Partitioning
      KOL-Index: 15487

      BACKGROUND: Stereotactic radiosurgery (SRS) and, more recently, fractionated stereotactic radiotherapy (SRT) have been recognized as noninvasive alternatives to surgery for the treatment of acoustic schwannomas. We review our experience of acoustic tumor treatments at one institution using a gamma knife for SRS and the first commercial world installation of a dedicated linac for SRT.

      METHODS: Patients were treated with SRS on the gamma knife or SRT on the linac from October 1994 through ...

      Known for Acoustic Schwannomas | Stereotactic Radiotherapy | Srs Srt | Gamma Knife | Comparative Observations
      KOL-Index: 15276

      The emergence of resistance to EGF receptor (EGFR) inhibitor therapy is a major clinical problem for patients with non-small cell lung cancer (NSCLC). The mechanisms underlying tumor resistance to inhibitors of the kinase activity of EGFR are not fully understood. Here, we found that inhibition of EGFR by erlotinib induces STAT3 phosphorylation at Tyr705 in association with increased Bcl2/Bcl-XL at both mRNA and protein levels in various human lung cancer cells. PTPMeg2 is a physiologic ...

      Known for Lung Cancer | Small Cell | Erlotinib Resistance | Stat3 Niclosamide | Protein Levels
      KOL-Index: 15242

      PURPOSE: To review the dose limits and standardize the three-dimenional (3D) radiographic definition for the organs at risk (OARs) for thoracic radiotherapy (RT), including the lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.

      METHODS AND MATERIALS: The present study was performed by representatives from the Radiation Therapy Oncology Group, European Organization for Research and Treatment of Cancer, and Soutwestern Oncology Group lung cancer committees. ...

      Known for Brachial Plexus | Spinal Cord | Thoracic Radiotherapy | Proximal Bronchial Tree | Dose Limits
      KOL-Index: 15234

      PURPOSE: The influence of tumor site, size, and extent of surgery on the survival of patients with glioblastoma multiforme treated on three consecutive prospectively randomized Radiation Therapy Oncology Group trials employing surgery and irradiation plus or minus chemotherapy was studied.

      METHODS AND MATERIALS: Six hundred forty-five patients with a diagnosis of glioblastoma multiforme on central pathological review were analyzed for survival with respect to known prognostic factors, ...

      Known for Glioblastoma Multiforme | Radiation Therapy | Surgical Resection | Extent Surgery | Patients Biopsy
      KOL-Index: 14694

      Cigarette smoking, either active or passive, is the most important risk factor in the development of human lung cancer. Mounting evidence indicates that cigarette smoke constituents not only contribute to tumorigenesis but also may increase the spread of cancer in the body. Nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is formed by nitrosation of nicotine and has been identified as the most potent carcinogen. NNK, an important component in cigarette smoke, may also ...

      Known for Cancer Cells | Pkcι Fak | Small Interfering Receptors | Cigarette Smoke | Migration Invasion
      KOL-Index: 14654

      PURPOSE: To determine the response rate, progression-free survival and overall survival, and toxicity of paclitaxel, etoposide, and cisplatin combined with accelerated hyperfractionated thoracic radiotherapy in patients with limited-disease (LD) small-cell lung cancer (SCLC).

      PATIENTS AND METHODS: LD-SCLC patients with measurable disease, Karnofsky performance score of > or = 70, and adequate organ function who were previously untreated were eligible for the study. Treatment was as ...

      Known for Cisplatin Chemotherapy | Radiation Therapy | Paclitaxel Etoposide | Lung Cancer | Limited Disease
      KOL-Index: 14497

      PURPOSE: Tumor response after nonoperative lung cancer therapy is traditionally evaluated by bidimensional measurement of maximum tumor diameters. The purpose of this analysis is to investigate whether tumor largest dimension (based on RECIST [Response Evaluation Criteria In Solid Tumors]), bidimensional tumor product, and volume correlate with each other in evaluating tumors of patients with locally advanced non-small-cell lung cancer (NSCLC). In addition, the pace of locally advanced ...

      Known for Tumor Volume | Lung Cancer | Patients Locally | Bidimensional Measurements | Advanced Nsclc
      KOL-Index: 14484

      BACKGROUND: The combination of chemotherapy with thoracic radiotherapy (TRT) compared with TRT alone has been shown to confer a survival advantage for good performance status patients with stage III non-small cell lung cancer. However, it is not known whether sequential or concurrent delivery of these therapies is the optimal combination strategy.

      METHODS: A total of 610 patients were randomly assigned to two concurrent regimens and one sequential chemotherapy and TRT regimen in a ...

      Known for Sequential Chemotherapy | Small Cell | Phase Iii | Arm 1 | 5 Weeks

      Key People For Radiation Therapy

      Top KOLs in the world
      Carlos A Perez
      radiation therapy uterine cervix tumor control
      James D Cox
      radiation therapy lung cancer small cell
      Ahmedin M Jemal
      united states breast cancer addis ababa
      Walter John Curran
      radiation therapy brain metastases lung cancer
      Ritsuko R Komaki
      lung cancer radiation therapy small cell
      Thomas F Pajak
      radiation therapy neck cancer late effects

      Department of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, GA, United States of America | Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA | Department of Radiation Oncology, E

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.